We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Higher Risk Myelodysplastic Syndrome (MDS) is a serious blood disorder where the bone marrow produces abnormal blood cells, leading to a higher risk of developing leukemia and requiring prompt medical intervention.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
